Alberta Children's Hospital

Running trials

• Not yet recruiting

  Neuromodulation During the Prodrome to Prevent Disabling Migraine Attacks in Youth

  NCT07772427· University of Calgary· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· argenx· Source

• Recruiting

  BCI@Home: Brain Computer Interface Solutions to Enable Youth Living With Severe Disabilities

  NCT07073378· University of Calgary· Source

• Recruiting

  A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

  NCT07160634· Phase 3· Solid Biosciences Inc.· Source

• Recruiting

  Magnesium Trial in Acute Asthma in Emergency Department

  NCT06785272· Phase 3· Suzanne Schuh· Source

• Enrolling by invitation

  Diabetes Transition Coordinator Study

  NCT06300047· University of Calgary· Source

• Recruiting

  Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

  NCT06942039· Early phase 1· C17 Council· Source

• Recruiting

  A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

  NCT07071519· Phase 3· AbbVie· Source

• Enrolling by invitation

  Arm More + Camp: An Implementation Study

  NCT07065916· University of Calgary· Source

• Recruiting

  A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  NCT06941272· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

  NCT07015801· University of Calgary· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

  NCT06208735· Phase 1· British Columbia Cancer Agency· Source

• Recruiting

  A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With Spinal Muscular Atrophy

  NCT06396325· Maryam Oskoui, MD, MSc, FRCPC, FAAN· Source

• Active, not recruiting

  NS-050/NCNP-03 in Boys With DMD (Meteor50)

  NCT06053814· Phase 1/2· NS Pharma, Inc.· Source

• Active, not recruiting

  STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

  NCT06571383· Phase 4· Novo Nordisk A/S· Source

• Recruiting

  Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

  NCT06081348· Phase 2· Holland Bloorview Kids Rehabilitation Hospital· Source

• Recruiting

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

  NCT06392009· Phase 1/2· GRIN Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

  NCT06100744· Phase 3· AbbVie· Source

• Recruiting

  A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

  NCT06064097· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

  NCT06941389· University of Rochester· Source

• Not yet recruiting

  Visual Telerehabilitation in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour

  NCT06362434· University Health Network, Toronto· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

  NCT05996003· Phase 2· NS Pharma, Inc.· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05995353· Phase 3· AbbVie· Source

• Recruiting

  TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  NCT05848687· Phase 1/2· Tanja Andrea Gruber· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

  NCT05457556· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

  NCT05491525· Phase 2/3· Urovant Sciences GmbH· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Active, not recruiting

  Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder

  NCT05373719· Loulou Foundation· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Children's Oncology Group· Source

• Recruiting

  IMPACT: IMplementation of Physical Activity for Children and Adolescents on Treatment

  NCT04956133· University of Calgary· Source

• Recruiting

  Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour

  NCT05230758· Phase 3· Donald Mabbott· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· PedAL BCU, LLC· Source

• Recruiting

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  NCT05235165· Phase 3· Children's Oncology Group· Source

• Recruiting

  Evaluating the Impacts of a Single Session of Robot Assisted Gait Training With a Trexo

  NCT06407219· University of Calgary· Source

• Active, not recruiting

  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  NCT04994132· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

  NCT04687020· Phase 4· NS Pharma, Inc.· Source

• Recruiting

  Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

  NCT03938987· Phase 1/2· University of Alberta· Source

• Active, not recruiting

  Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

  NCT04281485· Phase 3· Pfizer· Source

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

  NCT04195399· Phase 2· Children's Oncology Group· Source

Showing 50 of 87.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers24 recruiting
• Acute lymphoblastic leukaemia7 recruiting
• Neuroblastoma4 recruiting
• Sarcoma4 recruiting
• Sickle cell disease4 recruiting
• Cerebral palsy3 recruiting
• Type 1 diabetes3 recruiting
• Acute myeloid leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Kidney cancer2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Spinal muscular atrophy2 recruiting
• Stroke2 recruiting
• Ulcerative colitis2 recruiting
• Asthma1 recruiting
• Autism1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Crohn's disease1 recruiting
• Down syndrome1 recruiting
• Fabry disease1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Hydrocephalus1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Tourette syndrome1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Creating an Engaging BCI/FES Therapy for Children With Perinatal Stroke Using Social Media

  NCT07133347· Phase 1· University of Calgary· Source

• Completed

  A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

  NCT05864846· Phase 4· Jazz Pharmaceuticals· Source

• Completed

  Robotic Walking for Children Who Cannot Walk

  NCT05473676· University of Calgary· Source

• Completed

  The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

  NCT05025852· Mount Sinai Hospital, Canada· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

  NCT05185622· Phase 2· Santhera Pharmaceuticals· Source

• Completed

  A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents

  NCT05102591· Phase 3· University of Calgary· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

  NCT05001737· Phase 3· Swedish Orphan Biovitrum· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

  NCT04378075· Phase 2/3· PTC Therapeutics· Source

• Terminated

  A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

  NCT04572243· Phase 3· Eisai Inc.· Source

• Completed

  HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

  NCT04670016· University of Calgary· Source

• Terminated

  A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

  NCT04029688· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer

  NCT03632343· The Hospital for Sick Children· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Parent Therapist Partnership to Provide Early, Intensive Exercise in Perinatal Stroke

  NCT03672864· University of Alberta· Source

• Completed

  COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

  NCT03206021· Phase 1· The Hospital for Sick Children· Source

• Completed

  Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

  NCT03376438· Edgar Jaeggi· Source

• Completed

  Re-Irradiation of Progressive or Recurrent DIPG

  NCT03126266· University of Calgary· Source

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Incyte Corporation· Source

• Completed

  Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

  NCT02800070· Phase 1· University Health Network, Toronto· Source

• Completed

  Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

  NCT02512926· Phase 1· Stanford University· Source

• Completed

  Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

  NCT02283853· Phase 3· Biogen· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Children's Oncology Group· Source

• Terminated

  Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

  NCT01247207· Phase 3· PTC Therapeutics· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Children's Oncology Group· Source

• Completed

  A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

  NCT00777036· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

  NCT00653068· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Children's Oncology Group· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Children's Oncology Group· Source

• Completed

  Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

  NCT00026312· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Children's Oncology Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Childhood cancers10 works · 79 trials
• Cerebral palsy8 works · 7 trials